Albert Mitrani is CEO & 10% at Organicell Regenerative Medicine, Inc. (BPSR). They have made 14 open-market trades across 1 company since 2015, most recently 2021-10-29.
CIK 0001644416
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $75K since 2015, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BPSR | 151,790,190 | — |
Shares reported on the most recent Form 4, priced at the 2021-11-02 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BPSR | SELL | 2021-06-17 | 2021-06-21 | $0.14 | $7K | N/A | N/A | N/A |
| BPSR | SELL | 2021-06-14 | 2021-06-16 | $0.15 | $29K | N/A | N/A | N/A |
| BPSR | SELL | 2021-06-09 | 2021-06-11 | $0.14 | $42K | N/A | N/A | N/A |
| BPSR | SELL | 2021-06-04 | 2021-06-08 | $0.13 | $33K | N/A | N/A | N/A |
| BPSR | SELL | 2021-06-01 | 2021-06-03 | $0.17 | $24K | N/A | N/A | N/A |
| BPSR | SELL | 2021-05-26 | 2021-05-28 | $0.18 | $35K | N/A | N/A | N/A |
| BPSR | SELL | 2021-05-21 | 2021-05-25 | $0.19 | $38K | N/A | N/A | N/A |
| BPSR | SELL | 2021-05-18 | 2021-05-20 | $0.21 | $53K | N/A | N/A | N/A |
| BPSR | SELL | 2021-05-13 | 2021-05-17 | $0.23 | $41K | N/A | N/A | N/A |
| BPSR | SELL | 2021-05-10 | 2021-05-12 | $0.29 | $51K | N/A | N/A | N/A |
| BPSR | SELL | 2021-05-05 | 2021-05-07 | $0.27 | $56K | N/A | N/A | N/A |
| BPSR | SELL | 2021-05-04 | 2021-05-05 | $0.40 | $20K | N/A | N/A | N/A |
| BPSR | SELL | 2021-04-29 | 2021-04-30 | $0.50 | $50K | N/A | N/A | N/A |
| BPSR | BUY | 2015-06-24 | 2015-06-26 | $0.01 | $75K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.